Trial 
concerns a 62 Years old Female patien . 
Medical History: Anemia of malignant disease, Non-small cell lung cancer. Concomitant Medication(s): prednisone, 
torasemide sodium, esomeprazole magnesium. 
On 29-NOV-2005, the patient received the first doses of pemetrexed (dose not reported). On 01-FEB-2006, the 
patient received the first dose of epoetin beta (30000 IU), subcutaneously (SC) for the treatment of anemia of 
malignant disease. Prior to the event, the last dose of pemetrexed was received on 16-MAR-2006. On 16-MAR-
2006, the patient experienced dyspnea and was hospitalized. The patient experienced similar symptoms in 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 483 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
previous chemotherapy/radiotherapy cycles. The patient was treated with furosemide for two days and the dyspnea 
resolved one week after onset. It was reported that no further information was available. 
In the opinion of the investigator, the event of dyspnea was considered related to pemetrexed and possibly related 
to pre-existing/underlying conditions of non-small cell lung carcinoma, lymphangial carcinomatoma and pleural 
effusion. The event was not considered to be related to epoetin beta. The relatedness to protocol procedures was 
not reported.